AASLD guidance covers semaglutide for MASH with moderate-to-advanced fibrosis

The American Association for the Study of Liver Diseases (AASLD) issued a November 2025 update to its practice guidance on using semaglutide to treat metabolic dysfunction–associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis, following the FDA's accelerated approval of the Wegovy formulation on August 15, 2025 ^[1]. The update builds on AASLD's 2023 guidance for fatty liver disease, now called MASLD ^[1].

The guidance says the approval covers MASH with stage F2–F3 fibrosis and draws on the first 800 participants enrolled in the phase 3 ESSENCE trial (NCT04822181) ^[1]. After 72 weeks of semaglutide 2.4 mg once weekly by subcutaneous injection, 62.9% of patients had MASH resolve without worsening of fibrosis, compared with 34.3% on placebo, and 36.8% had at least a one-stage reduction in liver fibrosis without worsening of MASH, compared with 22.4% on placebo. Both differences were statistically significant (p<0.001) ^[1].

How patients are selected

The trial enrolled people with biopsy-confirmed MASH, but the guidance says biopsy is not practical for choosing most patients in routine care and that the FDA label does not require it ^[1]. It recommends non-invasive tests (NITs) instead. A FIB-4 score below 1.3 rules out advanced fibrosis (stage F3 or higher) in 99% of all patients and 95% of patients with multiple cardiometabolic risks, but AASLD says FIB-4 should not be used by itself to decide who can get semaglutide ^[1].

The guidance supports these ranges for treatment candidates: VCTE liver stiffness of 8–15 kPa, MRE of 3.1–4.4 kPa, or ELF of 9.2–10.5 ^[1]. In an in-between zone — VCTE 15–20 kPa, MRE 4.4–5 kPa, or ELF 10.5–11.3 — the decision should be made case by case, the guidance says, based on ruling out cirrhosis with another confirmatory NIT, cross-sectional imaging that excludes a nodular-appearing liver contour and signs of portal hypertension, or a platelet count below 150,000/mm3 ^[1]. In ESSENCE, the median VCTE liver stiffness at the start was 10.8 kPa in the semaglutide group and 11.1 kPa in the placebo group, and the recommended 8–15 kPa range covered about half the study population ^[1].

Semaglutide is not approved for MASH cirrhosis, which the guidance defines as VCTE above 20 kPa, MRE above 5.0 kPa, ELF above 11.3, or evidence of portal hypertension. People with compensated cirrhosis who are taking semaglutide for another FDA-approved reason should be monitored carefully ^[1].

Safety and response

In ESSENCE, no participants stopped treatment because of liver enzyme elevations, and the guidance recommends routine liver panels only as clinically indicated ^[1]. The most common side effects were gastrointestinal — nausea, diarrhea, constipation and vomiting — generally mild and transient, and the guidance says patient education and dose titration help improve tolerance ^[1]. Clinicians are told to watch for rare but serious risks: acute kidney injury from dehydration, symptomatic gallbladder disease, pancreatitis, thyroid C-cell tumors, retinopathy progression, and loss of lean body mass ^[1].

No NIT reliably predicts who will respond, according to the guidance, but it points to changes from the start of treatment to 72 weeks as signals: an ALT drop of at least 17 U/L or 20%, VCTE liver stiffness down at least 30%, MRE down at least 20%, or ELF down at least 0.5 ^[1]. Worsening ALT or NIT results may suggest non-response, and the guidance says the benefit is uncertain in that case ^[1]. Lifestyle modification remains the cornerstone of MASH care alongside the drug, and combining semaglutide with resmetirom has not been studied ^[1].

Why it matters for patients

The guidance gives clinicians a way to identify eligible patients without sending everyone for a liver biopsy. Many people first learn they may have liver scarring from a FIB-4 score calculated from routine bloodwork; the guidance describes a sequence in which imaging or blood-based tests are used afterward to estimate fibrosis stage ^[1]. That matters because the FDA approval applies to a specific group — MASH with moderate-to-advanced fibrosis — and not to everyone with fatty liver disease ^[1].

It also draws a clear line at cirrhosis. People already taking semaglutide for weight management or cardiovascular risk who also have cirrhosis fall into a group the guidance says should be watched carefully, even though the drug is not approved for MASH cirrhosis ^[1]. The guidance also notes that routine liver enzyme monitoring is not needed for everyone, while listing the gastrointestinal side effects and rarer risks that doctors are advised to track ^[1].

What happens next

The FDA's August 2025 decision was an accelerated approval, which the guidance says is contingent on verifying and describing clinical benefit in the ongoing phase 3 ESSENCE trial. Results are anticipated in 2028 or thereafter ^[1]. Until then, the evidence base for long-term outcomes in MASH remains incomplete, and the guidance notes that no non-invasive test reliably predicts an individual patient's response ^[1]. Costs, insurance coverage and access to the newly approved MASH indication are not addressed in the guidance ^[1].